| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-485 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-485 |
| filingDate |
1993-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1995-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b912edb07a3c1cbd1de69a742447768e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f17837bf9042820256bbd593771ae11f |
| publicationDate |
1995-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-5397770-A |
| titleOfInvention |
Yeast-derived epidermal growth factor/urogastrone-like products |
| abstract |
A medicinal composition comprising an Epidermal Growth Factor-like protein derived from yeast, and a carrier which is pharmaceutically acceptable and suitable for the type of administration and treatment for which the composition is to be used. The yeast-derived protein Has a molecular weight of about 4770 daltons and a murine Epidermal Growth Factor (mEGF) activity equivalent to at least 100 nanograms of mEGF by Elisa Assay Titration. The medicinal composition may be applied topically for purposes such as the treatment of external body wounds, or in ophthalmic surgery such as in cataract or corneal surgery, by incorporating a carrier therein which is pharmaceutically acceptable for the particular topical use. The composition may be administered orally for treatment of such ailments as peptic ulcers by incorporating therein a carrier which is pharmaceutically acceptable for oral administration in oral dosage form. Additionally, the present composition may be formulated in a suitable carrier for parenteral injection to promote bone and tendon repair in a warm blooded animal. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7190109-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5894018-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6138683-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6337320-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5776193-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5922346-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8030836-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8758418-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6187047-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010191172-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004143308-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6223071-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11241465-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9723991-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006251654-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004086531-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004220680-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003153500-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011052514-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6902584-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7842097-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9289460-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8216289-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6764517-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2013287715-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006014684-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007249716-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7723910-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6709446-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7238357-B2 |
| priorityDate |
1990-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |